Announcements Trials
Browse Landscape

Phase

Phase 3 19Phase 2 10Phase 1 2Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 3NIH 2NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Docetaxel 7Radiotherapy 6Vincristine 5Etoposide 5Cyclophosphamide 5Cisplatin 5Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Doxorubicin 4Carboplatin 4Capecitabine 4pembrolizumab 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Prednisone 3Oxaliplatin 3Methotrexate 3Leucovorin 3Fluorouracil 3Dexamethasone 3Cytarabine 3Calcium Dobesilate 3Surgical Procedures, Operative 2Ramucirumab 2Radiation 2Pemetrexed 2Mitomycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NETWORK × Asparaginase × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡